Skip to main content
Theranostics logoLink to Theranostics
. 2020 Jan 18;10(5):2401. doi: 10.7150/thno.42848

Enhanced Blood Suspensibility and Laser-Activated Tumor-specific Drug Release of Theranostic Mesoporous Silica Nanoparticles by Functionalizing with Erythrocyte Membranes: Erratum

Jinghan Su 1,2, Huiping Sun 1,3, Qingshuo Meng 1,2, Pengcheng Zhang 1, Qi Yin 1, Yaping Li 1,2,
PMCID: PMC7019168  PMID: 32104511

In the initially published version of this article, the “Heart” image of the RMSNs+Laser group in Figure 7 is wrong. The correct Figure 7 is as follow:

Figure 7.

Figure 7

H&E staining of heart, liver, spleen and kidney (100×) at the end of the antitumor inhibition test. The black circles indicated the inflammation in the heart of the Dox-treated mice. Scale bar = 100 μm.

The corrections made in this erratum do not affect the original conclusions. The authors apologize for any inconvenience or misunderstanding that this error may have caused.

References

  • 1.Su J, Sun H, Meng Q, Zhang P, Yin Q, Li Y. Enhanced Blood Suspensibility and Laser-Activated Tumor-specific Drug Release of Theranostic Mesoporous Silica Nanoparticles by Functionalizing with Erythrocyte Membranes. Theranostics. 2017;7(3):523–537. doi: 10.7150/thno.17259. doi:10.7150/thno.17259. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Theranostics are provided here courtesy of Ivyspring International Publisher

RESOURCES